Daewoong Pharmaceutical has filled the gap for Astellas Korea’s diarrhea-type irritable bowel syndrome treatment Irribow (ramosetron hydrochloride), which was discontinued in February this year.

The Ministry of Food and Drug Safety approved Daewoong Pharmaceutical's Irricol Tab 2.5㎍ (ramosetron hydrochloride) on the 20th. This follows Daewoong receiving approval for the lower dose of Irricol Tab 5㎍ on May 31, filling the gap left by Irribow’s absence.

There are 23 items approved for ramosetron hydrochloride in Korea, but except for Irricol, all of them have indications only for the prevention of digestive symptoms (nausea, vomiting) caused by the administration of anticancer drugs.

Lee, Hye-Kyung(hgrace7@dailypharm.com)